Federico Iacopini

Federico Iacopini

*This is an algorithmically generated author record based on publicly available information.

Federico Iacopini has a total of 161 co-authors. Here are the top co-authors by number of shared publications:

  • Guido Costamagna

    Digestive Endoscopy Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; Cattolica del Sacro CuoreUniversity, Centre for Endoscopic Research Therapeutics and Training CERTT, Roma, Italy; Université de Strasbourg Institut d'Etudes Avancées USIAS, Strasbourg, France

    3 shared publications
  • Patrizia Rigato

    Pathology Unit, Ospedale S. Giuseppe, Marino, Rome, Italy

    3 shared publications
  • Takuji Gotoda

    Division of Gastroenterology and Hepatology, Nihon University School of Medicine, Tokyo, Japan

    3 shared publications
  • Agostino Scozzarro

    2 shared publications
  • Alfredo Papa

    Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, 00168 Rome, Italy

    2 shared publications
  • Andrea Pasta

    Gastroenterology Unit, Department of Internal Medicine University of Genoa Genoa Italy

    2 shared publications

Latest Publications

  • Open Access

    Approach to Early Rectal Cancer in 2026: The Emerging Role of Endoscopic Intermuscular Dissection

    by Sara Schiavone, David J. Tate, Maria Eva Argenziano, Roberta Maselli, Cesare Hassan, Alessandro Repici, Gianluca Andrisani, Federico Iacopini, Giulio Antonelli

    Background/Objectives: The management of early rectal cancer is increasingly shifting toward organ-preserving strategies aimed at maintaining oncological efficacy while minimizing the morbidity and functional impairment associated with radical surgery. However, endoscopic submucosal dissection (ESD) may provide inadequate deep vertical margins in lesions with deep submucosal invasion. Endoscopic intermuscular dissection (EID) has recently emerged as a deeper resection technique that may address this therapeutic gap. This review summarizes current approaches to early rectal cancer and critically evaluates the emerging role of EID. Methods: A narrative review was conducted using PubMed and Scopus, including relevant English-language studies available through August 2026. Evidence on early rectal cancer, histopathological risk stratification, pre-resection assessment, surgical and endoscopic local excision techniques, oncological and functional outcomes, and management after non-curative resection was reviewed, with particular emphasis on EID. Recent studies and relevant guidelines were considered alongside earlier landmark publications. As a narrative review, the evidence was selected and synthesized without a systematic review protocol. Results: EID enables dissection between the circular and longitudinal layers of the muscularis propria, providing deeper vertical clearance than ESD while preserving rectal wall integrity. Available studies report en bloc and R0 resection rates of approximately 94–96% and 81–83%, respectively, with encouraging three-year oncological outcomes in selected patients with low- and intermediate-risk deep submucosal invasive cancer. However, current evidence is derived mainly from expert centers and limited cohorts, and uncertainties remain regarding proximal rectal lesions, subsequent completion surgery, and long-term oncological outcomes. Conclusions: EID represents a promising organ-preserving option for selected early rectal cancers with deep submucosal invasion, but should not yet be considered standard practice. In selected cT1N0 rectal lesions with suspected deep submucosal invasion, EID may provide greater vertical clearance when conventional ESD is unlikely to achieve an adequate deep resection margin. Expert optical assessment with virtual chromoendoscopy, pelvic MRI and, when appropriate, endorectal ultrasound (EUS), inform pre-resection staging and patient selection. Careful patient selection and multidisciplinary management remain essential, while prospective multicenter studies with longer follow-up are required to establish its oncological safety, reproducibility, and role in clinical practice.

  • Open Access

    Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study

    by Antonio Tursi, Giammarco Mocci, Francesco Costa, Linda Ceccarelli, Edoardo Savarino, Caterina De Barba, Caterina Mucherino, Elvira D’ANtonio, Laura Montesano, Manuela Marzo, et al.

    Background/Aims: Real-world data on the use of filgotinib (FILGO) in patients with ulcerative colitis (UC) are limited. This study aims to provide consistent results on the effectiveness and safety of FILGO in treating UC. Methods: A retrospective assessment of clinical and endoscopic activity was conducted in a cohort of patients with UC according to the full Mayo score. The primary co-endpoints of the study were the evaluation of the effectiveness and safety of FILGO. Results: We enrolled 102 patients with a median follow-up of 24 weeks (interquartile range, 8–24 weeks). At 8 weeks and the end of follow-up, clinical remission was achieved by 38 (37.2%) and 47 (46.1%) patients, respectively. Clinical remission was achieved in 13 of 18 patients (72.2%) receiving first-line therapy, 7 of 19 patients (36.8%) receiving second-line therapy, and 27 of 65 patients (41.5%) receiving third-line therapy (P= 0.002). Clinical remission at 8 weeks predicted clinical remission at the end of follow-up (P= 0.021). Age > 40 years (P= 0.046) and being on second- or third-line of treatment (P= 0.005) were negative predictors for clinical remission. Seventy-one patients (69.6%) achieved a clinical response. At endoscopic evaluation, mucosal healing was observed in 18 out of 30 patients (60.0%). Steroid-free remission was present in 38 out of 46 patients (82.6%). Five patients (4.9%) needed colectomy. Adverse events were recorded in 6 patients (5.8%): 2 cases (2%) were severe, requiring discontinuation of FILGO.Conclusions: Our real-world data confirms that FILGO is safe and effective for patients with UC. Its efficacy is significantly improved when used as a first-line treatment.


  • Open Access

    Upadacitinib’s Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World Study

    by Giammarco Mocci, Antonio Tursi, Franco Scaldaferri, Daniele Napolitano, Daniela Pugliese, Giovanni Maconi, Giovanni Cataletti, Roberta Pica, Claudio Cassieri, Edoardo Vincenzo Savarino, et al.

    Background: Upadacitinib (UPA), a selective anti-JAK1 agent, obtained refundability from the Italian National Health System in July 2023 for its use in patients with ulcerative colitis (UC) refractory to other therapies, including anti-TNF-α, anti-integrins, and ustekinumab. At present, no Italian data are available about its effectiveness and safety in the real world. Methods: A retrospective assessment of clinical and endoscopic activity was performed according to the Mayo score. The primary endpoints were to evaluate the effectiveness and safety of UPA. Results: We included 202 consecutive UC patients (M/F 119/83, median age 42). The clinical remission and clinical response rates were 45.5% (92/202) and 63.5% (128/202), respectively, at 8 weeks and 60.2% and 81.7%, respectively, at the end of the follow-up. Clinical remission was achieved more frequently when UPA was used as a first-line rather than a second-/third-line treatment (p = 0.609). Mucosal healing was reported in 84.6% of patients at the median follow-up time. Adverse events occurred in six patients (2.5%), whereas four patients (2%) underwent colectomy. Conclusions: This large real-world study shows that UPA is an effective and safe treatment for UC patients.


  • Open Access

    Clinical consequences of computer-aided colorectal polyp detection

    by Pieter Sinonquel, Tom Eelbode, Oliver Pech, Dominiek De Wulf, Pieter Dewint, Helmut Neumann, Giulio Antonelli, Federico Iacopini, David Tate, Arnaud Lemmers, et al.

    Background and aim Randomised trials show improved polyp detection with computer-aided detection (CADe), mostly of small lesions. However, operator and selection bias may affect CADe’s true benefit. Clinical outcomes of increased detection have not yet been fully elucidated. Methods In this multicentre trial, CADe combining convolutional and recurrent neural networks was used for polyp detection. Blinded endoscopists were monitored in real time by a second observer with CADe access. CADe detections prompted reinspection. Adenoma detection rates (ADR) and polyp detection rates were measured prestudy and poststudy. Histological assessments were done by independent histopathologists. The primary outcome compared polyp detection between endoscopists and CADe. Results In 946 patients (51.9% male, mean age 64), a total of 2141 polyps were identified, including 989 adenomas. CADe was not superior to human polyp detection (sensitivity 94.6% vs 96.0%) but outperformed them when restricted to adenomas. Unblinding led to an additional yield of 86 true positive polyp detections (1.1% ADR increase per patient; 73.8% were Conclusion Even if CADe appears to be slightly more sensitive than human endoscopists, the additional gain in ADR was minimal and follow-up intervals rarely changed. Additional inspection of non-neoplastic lesions was increased, adding to the inspection and/or polypectomy workload.


  • Endoscopic submucosal dissection: Italian national survey on current practices, training and outcomes

    by Roberta Maselli, Federico Iacopini, Francesco Azzolini, Lucio Petruzziello, Mauro Manno, Luca De Luca, Paolo Cecinato, Giancarla Fiori, Teresa Staiano, Erik Rosa Rizzotto, et al.


  • Open Access

    Colorectal endoscopic submucosal dissection: predictors and neoplasm-related gradients of difficulty

    by Federico Iacopini, Yutaka Saito, Antonino Bella, Takuji Gotoda, Patrizia Rigato, Walter Elisei, Fabrizio Montagnese, Giampaolo Iacopini, Guido Costamagna

    Background and study aim The role of colorectal endoscopic submucosal dissection (ESD) is standardized in Japan and East Asia, but technical difficulties hinder its diffusion. The aim was to identify predictors of difficulty for each neoplasm type. Methods A competent operator performed all procedures. ESD difficulty was defined as: en bloc with a slow speed (< 0.07 cm2/min; 30 × 30 mm neoplasm in > 90 min), conversion to endoscopic mucosal resection, or resection abandonment. Pre- and intraoperative difficulty variables were defined according to standard criteria, and evaluated separately for the rectum and colon. Difficulty predictors and gradients were evaluated by the multivariate logistic regression model. Results A total of 140 ESDs were included: 110 in the colon and 30 in the rectum. Neoplasms were laterally spreading tumors – granular type (LST-G) in 85 cases (61 %); the median longer axis was 30 mm (range 15 – 180 mm); a scar was present in 15 cases (11 %). ESD en bloc resection and difficulty rates were 85 % (n = 94) and 35 % (n = 39) in the colon, and 73 % (n = 22) and 50 % (n = 15) in the rectum (P = 0.17 and 0.28, respectively). The scar was the only preoperative predictor of difficulty in the rectum (odds ratio [OR] 12.3, 95 % confidence interval [CI] 1.27 – 118.36), whereas predictors in the colon were: scar (OR 12.7, 95 %CI 1.15 – 139.24), LST – nongranular type (NG) (OR 10.5, 95 %CI 1.20 – 55.14), and sessile polyp morphology (OR 3.1, 95 %CI 1.18 – 10.39). Size > 7 – ≤ 12 cm2 (OR 0.20, 95 %CI 0.06 – 0.74) and operator experience > 120 procedures (OR 0.19, 95 %CI 0.04 – 0.81) were predictors for a easy procedure. No intraoperative predictors of difficulty were identified in the rectum, whereas predictors in the colon were: severe submucosal fibrosis (OR 21.9, 95 %CI 2.11 – 225.64), ineffective submucosal exposure by gravity countertraction (OR 12.3, 95 %CI 2.43 – 62.08), and perpendicular submucosal dissection approach (OR 5.2, 95 %CI 1.07 – 25.03). When experience was /= 90, preoperative gradient of colonic ESD difficulty was the highest for LST-NGs (scar positive and negative up to 47 % and 20 %, respectively), intermediate for sessile polyps with scar (up to 23 %), and the lowest for LST-Gs (< 8 %). Different difficulty gradients between neoplasm types persisted with increasing experience: LST-NG rate up to 14 % after 120 procedures. Conclusions Colonic and rectal ESD difficulty has qualitative differences. Preoperative predictors should be considered to identify the difficulty gradient of each neoplasm type and the appropriate setting for ESD.


  • Open Access

    Underwater endoscopic submucosal dissection of a nonpolypoid superficial tumor spreading into the appendix

    by Federico Iacopini, Takuji Gotoda, Fabrizio Montagnese, Fabio Andrei, Yutaka Saito